Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0S0RS
|
||||
| Former ID |
DIB010114
|
||||
| Drug Name |
MK-8245
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Type 2 diabetes [ICD9: 250; ICD10:E11] | Phase 2 | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C17H16BrFN6O4
|
||||
| Canonical SMILES |
OC(=O)Cn1nnc(n1)c2onc(c2)N3CCC(CC3)Oc4cc(F)ccc4Br
|
||||
| InChI |
1S/C17H16BrFN6O4/c18-12-2-1-10(19)7-13(12)28-11-3-5-24(6-4-11)15-8-14(29-22-15)17-20-23-25(21-17)9-16(26)27/h1-2,7-8,11H,3-6,9H2,(H,26,27)
|
||||
| InChIKey |
UJEAABFSXKCSGI-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Acyl-CoA desaturase | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Metabolic pathways | ||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00846391) A Study to Assess the Safety and Efficacy of MK8245 in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK8245-005 AM2). U.S. National Institutes of Health. | ||||
| REF 2 | Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. J Med Chem. 2011 Jul 28;54(14):5082-96. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.